What should an AOD-9604 price Australia quotation itemise?
A research quotation that lists only milligrams and a dollar figure is incomplete. For AOD-9604, the price line should be read against a matching certificate of analysis and a batch identifier that appears on the vial label, the invoice and the analytical report. At minimum the quote should state the labelled peptide mass per vial, the number of vials, whether every vial shares one parent lot, the HPLC purity as area percent with the detection wavelength, the identity method (typically electrospray ionisation mass spectrometry), the counter-ion if known, a water-content result if determined, and the report date. Without those fields two Australian prices cannot be compared, because one vendor may be selling labelled mass of a lyophilised cake that includes counter-ion and residual moisture, while another is closer to net peptide content.
The name on the quote must be internally consistent. Anti-doping analytical papers treat AOD9604 / AOD-9604 as a discrete peptide analyte, not as intact human growth hormone. If a quotation mixes a fragment descriptor, a proprietary code and an informal synonym, the CoA sequence or composition table should resolve the ambiguity before the price is accepted.
Fulfilment terms belong beside the unit price. Local Australian stock and tracked dispatch change landed cost because they keep the lot number on a single courier trail and they reduce missing-paperwork events. Quotes that omit GST treatment, dispatch origin, and whether a PDF CoA accompanies the vials are not like-for-like. If the supplier chromatogram lacks integration parameters or a method reference, the receiving laboratory will spend instrument time establishing identity and purity; that labour is part of the true cost of an under-documented vial.
Specification language should be numerical. “Research grade” is not a result. The quotation should point to a minimum HPLC area-percent, a mass-match window, and a related-substance reporting threshold. A multi-vial order from one purified lot can share a single CoA; mixed lots require multiple reports. If the quote is silent on lot unity, budget extra documentation work.
How should HPLC purity be compared before accepting a unit price?
Reversed-phase HPLC is the usual purity assignment for synthetic AOD-9604 lots. Area percent at a stated wavelength is not a mass fraction and is not transferable between methods. A 99% figure obtained with a shallow gradient, a high-resolution C18 column and integration of all peaks above a low area threshold is not the same result as a 99% figure from a short, steep gradient that leaves related substances in the baseline. When two Australian prices differ widely, the first technical question is whether the HPLC methods are comparable.
The CoA should identify column chemistry, mobile-phase modifiers, gradient table, flow rate, column temperature, injection amount, and integration events (peak width, threshold, shoulder detection). Trifluoroacetic acid as an ion-pair reagent often improves UV peak shape at low wavelength, whereas formic acid is commonly chosen when the eluent is directed to a mass spectrometer. Purity values generated under those two regimes should not be treated as interchangeable when ranking quotes.
Related-substance control is a principal cost driver. Preparative HPLC that removes deletion sequences, incompletely deprotected species and oxidation products reduces isolated yield and raises the cost per labelled milligram. A lower price may indicate a shorter purification, a higher reporting threshold, or both. Laboratories should require a peak table, not only a headline percent. Shoulders that co-elute with the main component are not captured by integrating a single lump; diode-array peak-purity indices or an orthogonal chromatographic mode are the usual challenges to that lump, and those measurements have a method cost.
System suitability belongs beside the chromatogram. Retention-time windows, tailing factor and replicate-injection precision show whether the reported purity is an analytical result or an untested snapshot. Without suitability data, a high purity number is a weak justification for a high price, and a low price is a weak justification for skipping the check.
Which identity tests support the material named on an AOD-9604 invoice?
Price is being asked for a named peptide, so the lot must be shown to be that analyte. Electrospray ionisation mass spectrometry is the routine identity test. The CoA should report the observed mass, or the deconvoluted average or monoisotopic mass, against a theoretical value, preferably with the charge-state series listed. A single nominal-mass match without charge-state assignment is a weak identity claim and should not command a premium.
Cox HD et al. described detection and in vitro metabolism of AOD9604. For a receiving laboratory that result does two documentary jobs. It shows that the peptide is a defined LC-MS analyte with published detection methodology, and it illustrates that transformation products can appear as related masses when impurity peaks are interpreted. Those observations are method-development notes. A supplier price that includes a full-scan or tandem-MS listing is easier to reconcile with that published detection context than a price that includes only a UV chromatogram.
A. K. Orlovius et al. reported that AOD-9604 does not influence the WADA hGH isoform immunoassay. In a procurement file that statement is about selectivity. An hGH isoform immunoassay is not a substitute identity test for this peptide, and a quotation should not imply that kits designed for intact hGH isoforms will confirm AOD-9604. The peptide and intact hGH isoforms are distinguishable in that immunoassay format. A negative immunoassay result is therefore not evidence that a vial is empty or mislabelled; a peptide-specific LC-MS method is required.
Orthogonal identity—accurate mass plus fragment ions, or amino-acid analysis plus MS—consumes more instrument time and is often visible in the quote. Sequence-level tandem MS is the stronger basis for a higher Australian unit price because it reduces the risk that a similar-mass analogue has been substituted. None of these tests implies a use; they bind the invoice name to a molecular identity.
How do net peptide content, counter-ion and water change price per milligram?
Labelled milligrams on a lyophilised vial are not, by default, milligrams of anhydrous free peptide. Residual trifluoroacetate or acetate, residual water and process-related salts contribute to the cake mass. Two lots with the same labelled mass and the same HPLC area-percent can therefore contain different amounts of the intended peptide. The interpretable AOD-9604 unit cost is the price per net peptide milligram, or per micromole, after those corrections—not the price per vial headline.
Net peptide content is commonly estimated by amino-acid analysis, nitrogen content, or a calibrated ultraviolet response where the chromophore behaviour is understood. Counter-ion quantification and water by Karl Fischer titration complete the mass balance. If a quotation is silent on all three, the buyer is paying for an unallocated solid. A higher list price that includes those results may be lower on a net-content basis than a bargain vial with no content data.
This arithmetic also explains why bulk and single-vial catalogue lines diverge. Spreading one set of content assays across many vials reduces the documentation cost per milligram; a single vial that carries a full CoA bears the whole analytical overhead. When an Australian quote is compared with an overseas list, convert both to net peptide mass and add the local cost of repeating identity and purity tests if the overseas chromatogram is not method-traceable. GST, payment fees and tracked dispatch then sit on the same normalised milligram.
Acetate versus trifluoroacetate is a compositional fact, not a quality slogan. It changes the conversion from labelled mass to peptide moles. A laboratory that prepares quantitative HPLC standards without that conversion will mis-assign concentrations. Requesting the content data before accepting a price is ordinary laboratory practice.
Which CoA fields and Australian fulfilment terms justify paying more?
A certificate of analysis is the footnote to the price. For AOD-9604 it should carry a unique lot or batch number, appearance, identity result, HPLC purity table, content or counter-ion data if measured, water or residual solvent if measured, method names, test date, and a research-use-only statement. Sign-off and page count matter: a one-line purity email is not a CoA. The lot number on the vial, the CoA and the dispatch note should match. That loop is the minimum traceability a laboratory should pay for.
Australian fulfilment should be stated plainly. Local stock means the quoted lot is already in an Australian warehouse and can be picked without silent substitution. Tracked dispatch means the consignment identifier links the packed lot to goods-in. Those terms reduce missing CoAs, mixed lots and unidentifiable parcels, and they are costed into a professional quote. They do not replace spectra, and they are not a storage protocol.
Raw data volume is a legitimate price difference. Peak tables, chromatograms and mass spectra allow the receiving analyst to repeat integration decisions. A premium that buys those files is a premium for reduced method work on arrival. A cheaper quote with no spectra transfers the full identity burden to the buyer; that labour still belongs in an AOD-9604 price Australia budget.
Keep the procurement file free of homonym contamination. In Australia, “AOD” also denotes alcohol and other drug nursing demographics and treatment expenditure, and atmospheric science uses AOD for aerosol optical depth; Searby et al., Ritter et al., and Song et al. illustrate those unrelated usages. They do not characterise this peptide. The analytical trail is the HPLC and LC-MS file, together with published detection work on AOD9604 and the immunoassay-selectivity result versus hGH isoforms. Research-use labelling should remain on the quote, the CoA and the vial.
Order Aod 9604 with documentation
If this guide helped you evaluate Aod 9604 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Aod 9604 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why do two AOD-9604 quotes in Australia differ for the same labelled milligrams?
Two quotes can list the same labelled milligrams and still differ in net peptide content, HPLC method, related-substance reporting, and whether mass spectra are supplied. Local stock, tracked dispatch, GST treatment and single-lot versus mixed-lot supply also change landed cost. Normalise to net peptide milligrams and require matching chromatograms before ranking the figures.
Is a headline HPLC purity enough to accept a research price?
No. Area-percent is not transferable between methods. Without the column chemistry, gradient, detection wavelength, integration threshold and system-suitability results, a 98% figure cannot be compared with another 98% figure. Ask for the peak table and the method reference; those files are part of what the price is paying for.
What identity data should a research CoA include for AOD-9604?
A research CoA should report an electrospray mass that matches the theoretical value, with charge states listed. Tandem-MS fragments strengthen the claim. Cox HD et al. described LC-MS detection of AOD9604; Orlovius et al. showed that a WADA hGH isoform immunoassay is not an identity test for this peptide.
How should net peptide content be used when comparing unit price?
Use net peptide milligrams, not labelled milligrams. Residual counter-ion and water inflate cake mass, so a cheaper vial can contain less peptide. Divide the lot price by the content-corrected mass, or by micromoles, and only then compare Australian quotes. If content was not measured, treat the unit price as incomplete.
Is AOD-9604 from ClaraScience supplied as a research material only?
Yes. ClaraScience lists AOD-9604 as a research material only. The quotation, CoA and vial should carry a research-use-only statement. This article does not give laboratory protocols for biological systems and does not attribute any physiological outcome to the peptide.
Why do unrelated Australian “AOD” papers appear beside peptide searches?
In Australian health literature AOD commonly means alcohol and other drugs, including nursing workforce studies and treatment-expenditure estimates. Atmospheric science uses AOD for aerosol optical depth. Neither usage describes the synthetic peptide, and those papers should not be filed against a peptide lot.
References
- PMID:25208511 — Detection and in vitro metabolism of AOD9604 — Drug Test Anal — 2015
- DOI:10.1002/dta.1557 — AOD‐9604 does not influence the WADA hGH isoform immunoassay — Drug Testing and Analysis — 2013
- DOI:10.1016/j.colegn.2021.03.006 — The demographic profile of alcohol and other drug (AOD) nurses in Australia: Experienced, highly qualified… and endangered? — Collegian — 2022
- DOI:10.1111/dar.12248 — Health expenditure on alcohol and other drug treatment in Australia (2012/2013) — Drug and Alcohol Review — 2015
- DOI:10.1007/s00704-017-2142-5 — Weekday AOD smaller than weekend AOD in eastern China on the basis of the MODIS AOD product — Theoretical and Applied Climatology — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
